New hope for lung cancer patients after other treatments fail
NCT ID NCT07154368
Summary
This study is testing a new oral drug called JYP0322 against standard chemotherapy for people with advanced lung cancer that has a specific genetic change (ROS1-positive) and has stopped responding to previous targeted therapies. About 207 participants will be randomly assigned to receive either the new pill three times daily or intravenous chemotherapy every three weeks. The main goal is to see which treatment better delays the cancer from getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.